Cannabis Medicinal Use
Cannabinoids and Cancer
The use of cannabinoids in treating the side effects of cancer chemotherapy is more widely-studied than many other potential therapeutic applications, and a number of clinical studies have taken place investigating the use of THC and synthetic cannabinoids as anti-emetic agents. Two preparations have been licensed for use in clinical treatment either in the UK or elsewhere, including dronabinol (synthetic THC) and Nabilone (a novel synthetic cannabinoid).
Side effects of chemotherapy and wasting diseases: The powerful drugs used in cancer chemotherapy effectively kill reproducing cells, including both the malignant tumour cells and also, as a side effect, many cells continually reproducing such as hair follicle cells and those lining the gut, leading to severe nausea & vomiting. These side effects can be very severe and many patients find these difficult or impossible to tolerate, falling into a wasting syndrome through malnutrition brought on by a combination of reduced appetite and poor gastrointestinal efficiency, which can itself shorten life expectancy.
There is variation between the effects of different anti-cancer drugs. Cisplatin, one of the most effective chemotherapy agents, induces vomiting in over 99% of patients not taking an antiemetic, with around 10 vomiting episodes per dose, although methotrexate causes emesis in under 10% of patients   
There are also variations in the efficacy and side effects between conventional drugs used to treat nausea and vomiting. The BMA  listed the side effects of commonly-used anti-emetic drugs as follows:
(a) Phenothiazines (prochlorperazine, haloperidol) - severe dystonic reactions, drowsiness, dry mouth, blurred vision, urinary retention, hypotension (low blood pressure), allergic reactions, occasional jaundice.
(b) Metoclopramide - acute dystonic reactions, facial and muscle spasms, drowsiness, restlessness, diarrhoea, depression
(c) Domperidone - acute dystonic reactions
(d) SSRAs (Ondansetron, gransisetron) - constipation, headache, altered liver function. 
The main beneficial effects reported from use of cannabinoids are a reduction in the incidence and severity of nausea and vomiting (emesis), and stimulation of appetite, together reducing the severity of cachexia - wasting syndrome - in patients receiving chemotherapy treatment.
Jamshidi & Taylor  discovered "intrahypothalamic anandamide initiates appetite by stimulation of CB1 receptors, thus providing evidence on the involvement of hypothalamic endocannabinoids in appetite initiation." Inui  concluded "cannabinoids... act on the feeding-regulatory circuitry to increase appetite and inhibit tumor-derived catabolic factors to antagonize tissue wasting and/or host cytokine release. Because weight loss shortens the survival time of cancer patients and decreases performance status, effective therapy would extend patient survival and improve quality of life."
In a 2003 review, Croxford  noted "Dronabinol, a commercially available form of delta(9)-THC, has been used successfully for increasing appetite in patients with HIV wasting disease", similarly, Walsh et al  noted "The two proven indications for the use of the synthetic cannabinoid (dronabinol) are chemotherapy-induced nausea and vomiting and AIDS-related anorexia. Other possible effects that may prove beneficial in the oncology population include analgesia, antitumor effect, mood elevation, muscle relaxation, and relief of insomnia." Grotenhermen  agreed "Properties of cannabis that might be of therapeutic use include analgesia, muscle relaxation, immunosuppression, sedation, improvement of mood, stimulation of appetite, antiemesis, lowering of intraocular pressure, bronchodilation, neuroprotection and induction of apoptosis in cancer cells." Parker et al  concluded "endogenous cannabinoids play a role in modulation of nausea". Zurcher  recommended cannabinoids for treatment of cancer-induced anorexia.
However Taskhin et al warned "The potential for marijuana smoking to predispose to the development of respiratory malignancy is suggested by several lines of evidence, including the presence of potent carcinogens in marijuana smoke and their resulting deposition in the lung, the occurrence of premalignant changes in bronchial biopsies obtained from smokers of marijuana in the absence of tobacco, impairment of antitumor immune defenses by delta9-tetrahydrocannabinol, and several clinical case series in which marijuana smokers were disproportionately over represented among young individuals who developed upper or lower respiratory tract cancer. Additional well designed epidemiological and immune monitoring studies are required to determine the potential causal relationship between marijuana use and the development of respiratory infection and/or cancer." and Russmann et al  reported a case history of a patient suffering a fatal stroke after smoking cannabis during a session of cisplatin chemotherapy for testicular cancer. In a general review, Drewe  noted "Chronic marijuana smoking is associated with increased toxicity and the risk of cancer of the respiratory tract. There is evidence of disturbance of the immune system and teratogenic effects of chronic cannabis use". Gardner et al  found methanandamide "resulted in an increased rate of tumor growth" in mouse lung cells, but noted "methanandamide augments tumor growth by a cannabinoid receptor-independent pathway"
Clinical Trials involving THC: Sallan et al (1975)  found 10mg THC Æsignificantly more effectiveÃ than placebo at reducing nausea and vomiting in 22 chemotherapy patients. Chang et al  (1979) found 10mg oral or 17mg smoked THC to decrease methotrexate-induced nausea and vomiting compared to placebo in 14 of 15 patients. Frytak et al  found 15mg THC better than placebo at inhibiting prochorperazine-induced emesis, but noted some of the 116 gastrointestinal cancer patients to find the side effects (sedation, ÆhighÃ dysphoria, hypotension & tachycardia) intolerable. Orr & McKearnan  found 7mg THC to be more effective than prochlorperazine and placebo in 55 patients, of which 82% reported a high. Lucas & Laszlo  found 15mg or 2x5mg THC more effective than placebo or standard regimes.
However Chang et al  found 3-hourly oral (10mg) or smoked (17.4mg) THC ineffective compared with placebo in a small study of 8 patients receiving adriamycin and cyclophosphamide. Niedhart et al  compared THC and Haloperidol in 52 chemotherapy patients finding no difference in efficacy between the two drugs. Gralla et al  found 10mg THC more effective than placebo, but less effective than metoclopramide in controlling cisplatin-induced vomiting in a 27-patient study. Ungerleider et al  in a large study of 214 patients, found 4-hourly 7.5-12.5mg THC and 10mg prochlorperazine equally effective in reducing nausea and vomiting, but noted THC was preferred by more patients. Lane et al  found significant improvement both with THC (10mg dronabinol) and prochlorperazine, and the combination more effective than either alone in abolishing nausea and vomiting in 62 patients.
Clinical Trials involving Nabilone: Nagy et al  studied 47 patients receiving cisplatin, finding nabilone more effective than prochlorperazine or placebo in reducing nausea & vomiting caused by cisplatin. Herman et al  found similar results with 113 patients receiving cisplatin, cyclophosphamide & mustine therapy. Einhorn et al  studied 100 chemotherapy patients, finding nabilone significantly more effective than prochlorperazine and preferred by 75% of patients, but noted lethargy and hypotension, similar results found in studies of 114 patients by Wada et al  , in 36 patients by Levitt et al  , 18 patients by Johannson et al  , 26 patients by Ahmedzal et al  and 24 patients by Niranan & Mattison  .
Jones et al  found Æsignificant reduction in nausea and vomiting with nabilone compared to placeboÃ in a study of 54 patients and noted acceptable side effects to include dizziness (65%) and drowsiness (51%). Niederle et al  found nabilone significantly better than alizapride in reducing cisplatin-induced nausea & vomiting in 20 patients. Pomeroy et al  found nabilone superior to domperidone in reducing vomiting episodes among 38 patients, as did Dalzell et al  in a study of 23 children, finding that despite more side effects it was preferred by two thirds of respondents, and a study of 30 children by Chan et al  found nabilone superior to prochlorperazine.
Studies involving natural cannabis: Vinciguerra et al  studied 56 cancer patients unresponsive to conventional antiemetic agents, who were asked to rate the effectiveness of marijuana compared to prior chemotherapy cycles. Smoked marijuana was rated as "moderately effective" or "highly effective." by 78% of patients. The authors concluded that marijuana had antiemetic efficacy, but no control group was used and the patient population varied with respect to prior marijuana use or THC therapy.
A double-blind, cross-over, placebo-controlled study by Levitt et al  compared smoked marijuana with oral THC among 20 patients receiving a variety of chemotherapy drugs. The efficacy was similar, with 25% of patients achieving complete control over vomiting. Seven patients (35%) indicated apreference for oral THC over marijuana; 4 patients (20%) preferred smoked marijuana and 9 patients (45%) expressed no preference.
Neither study investigated the time course of antiemetic control, advantages of self-titration with the smoked marijuana, or ability of patients to swallow the pills. Patients with severe vomiting are unlikely to be able to swallow or keep pills down long enough for them to take effect. The onset of drug effect is much faster with smoked THC in cannabis than it is for oral delivery    , and the differences in cannabinoid content of smoked cannabis compared to the oral THC route can alter the users perceptions and subjective effects. Haney et al  reported smoked cannabis to make users feel ÆmellowÃ whereas oral THC did not. . Although many cannabis users claim that smoking the drug provides more effective relief from vomiting than oral THC, no controlled studies have yet been published which firmly establish this to be the case.
Conclusions of Major Recent Inquiries: The British Medical Association  concluded:
"Cannabinoids are undoubtedly effective as anti-emetic agents in vomiting induced by anti-cancer drugs" and that "Systematic trials of the effectiveness of cannabinoids in combatting vomiting resulting from different chemotherapy agents should be carried out".
The United States Institute of Medicine report  concluded:
"In patients already experiencing severe nausea or vomiting, pills are generally ineffective, because of the difficulty in swallowing or keeping a pill down, and slow onset of the drug effect. Thus an inhalation (but, preferably not smoking) cannabinoid drug delivery system would be advantageous for treating chemotherapy-induced nausea." ... "It is possible that the harmful effects of smoking marijuana for a limited period of time might be outweighed by the antiemetic benefits of marijuana, at least for, patients for whom standard antiemetic therapy is ineffective and who suffer from debilitating emesis. Such patients should be evaluated on a case by case basis"
The House of Lords Science & Technology Select Committee made the following findings and recommendations  :
"...cannabis and cannabinoids are likely to be of benefit as anti-emetics only to the small proportion of patients who do not respond to existing treatments, or possibly in the treatment of the delayed stages of emesis which can occur for some days following cancer chemotherapy, and which do not respond well to the serotonin antagonists. Nevertheless, cannabinoids are undoubtedly effective as antiemetics and more research in this field might explore their use in combination with the serotonin antagonists, help to determine for which patients they are most appropriate, and examine the potential of the allegedly less psychoactive cannabinoid D8THC, for which there have been encouraging preliminary clinical results"
"Unlike cannabis itself, the cannabinoid THC (dronabinol) and its analogue nabilone are already accepted by the Government as having medical value -- producing the anomaly that, while cannabis itself is banned as a psychoactive drug, THC, the principal substance which makes it psychoactive, is in legitimate medical use. Some of our witnesses are prepared to contemplate wider medical use of the cannabinoids, but not of cannabis itself. We disagree, since some users of both find cannabis itself more effective. We do, however, welcome the inclusion of THC in the trials proposed by the Asscher group, in like-for-like comparison with cannabis itself"
"Dronabinol (THC), though not licensed in this country, has already been moved to Schedule 2 to the Misuse of Drugs Regulations, and nabilone is a licensed medicine and not a controlled drug; so no Government action is required in either case to permit clinical trials or indeed prescription. ...we recommend that the Government should raise the matter of rescheduling the remaining cannabinoids with the WHO in due course, in order to facilitate research."
"Our principal reason for recommending that the law be changed, to make legal the use of cannabis for medical purposes, is compassionate. Illegal medical use of cannabis is quite widespread; it is sometimes connived at and even in some cases encouraged by health professionals; and yet at present it exposes patients and in some cases their carers to all the distress of criminal proceedings, with the possibility of serious penalties. We acknowledge that, if our recommendation were implemented, the United Kingdom would be moving out of step with many other countries; we consider that the Government should not be afraid to give a lead in this matter in a responsible way."
Recent scientific developments-anti-tumour activity: Recent scientific advances in the study of cannabinoid receptors and endocannabinoids have produced exciting new leads in the search for anti-cancer treatments, with CB1 and CB2 agonists (like THC) associated with tumour regression, reduced proliferation and blood supply to tumours, and apoptosis (programmed cell-suicide) among cells of various cancer types.
Blazquez et al  reported "Cannabinoids, the active components of marijuana and their derivatives, induce tumor regression in rodents... Inhibition of tumor angiogenesis may allow new strategies for the design of cannabinoid-based antitumoral therapies." Sanchez et al  reported "growth of the rat glioma (one of the most malignant forms of cancer) is inhibited by psychoactive cannabinoids" and that "local administration of (a) selective CB(2) agonist... induced a considerable regression of malignant tumors".
In a study of skin cancers, Casanova et al  found "In cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB(1)/CB(2) agonist WIN-55,212-2 or the selective CB(2) agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells. This was accompanied by impairment of tumor vascularization, as determined by altered blood vessel morphology and decreased expression of proangiogenic factors" Furthermore Di Marzo et al  noted the "anti-proliferative effect of anandamide in human breast cancer cells" was enhanced by Palmitoylethanolamide. De Petrocellis et al  considered this effect to be mediated by CB1 and vanilloid receptors. Fowler et al  concluded "the antiproliferative effects of anandamide were not solely mediated by either its hydrolysis to produce arachidonic acid or its CB receptor-mediated activation of phospholipase A(2) since palmitoyltrifluoromethyl ketone did not prevent the response to anandamide."
In a study of thyroid cancer cells, Portella et al  noted "Stimulation of cannabinoid CB1 receptors ... inhibits the growth of a rat thyroid cancer cell-derived tumor in athymic mice" and concluded "CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis" Mimeault et al  , studying prostate cancer, reported "The potent anti-proliferative and cytotoxic effects of (anandamide) on metastatic prostatic cancer cells might provide basis for the design of new therapeutic agents for effective treatment of recurrent and invasive prostatic cancers." Recht et al  found a metabolite of THC ajulemic acid (AJA; dimethylheptyl-THC-11-oic acid) to be "a potent anti-inflammatory agent without psychoactive properties... Its very favorable toxicity profile, including lack of psychoactivity, makes it suitable for chronic usage."
Studying the effect of cannabinoid receptor agonists and antagonists on different types of colorectal cancer cells, Ligresti et al  found "Anandamide, 2-AG, and the CBR agonist HU-210 potently inhibit CaCo-2 cell proliferation. This effect is blocked by the CB(1) antagonist SR141716A, but not by the CB(2) antagonist SR144528, and is mimicked by CB(1)-selective, but not CB(2)-selective, agonists. In DLD-1 cells, both CB(1) and CB(2) receptors mediate inhibition of proliferation." Jacobsson et al  concluded "the antiproliferative effects of the endocannabinoids upon (rat glioma) cells are brought about by a mechanism involving combined activation of both vanilloid receptors and to a lesser extent cannabinoid receptors" Gomez del Pulgar  et al found THC to cause death of glioma cells due to local synthesis of ceramide, and demonstrated  a neuroprotective effect of cannabinoids on astrocytes.
Gonzalez et al  found reduced CB1-receptor activity to be associated with development of pituitary cancers, noting "estrogen-induced pituitary hyperplastia was associated with a marked reduction in CB1 receptors" Pagotto et al  found elevated CB1 receptor activity and endocannabinoids in tumorous pituitary gland cells, noting "The results of this study point to a direct role of cannabinoids in the regulation of human pituitary hormone secretion." Rubovitch et al  demonstrated CB1-receptor-agonist modulated stimulation of calcium ion uptake in neuroblastoma cells. Bifulco et al  found an analogue of anandamide to inhibit oncogene-mediated tumour growth via CB1-receptor activity.
In a 2002 review. Guzman et al  concluded "cannabinoid administration induces regression of malignant gliomas in rodents by a mechanism that may involve sustained ceramide generation and extracellular signal-regulated kinase activation. In contrast, most of the experimental evidence indicates that cannabinoids may protect normal neurons from toxic insults, such as glutamatergic overstimulation, ischaemia, and oxidative damage. Regarding immune cells, low doses of cannabinoids may enhance proliferation, whereas high doses of cannabinoids usually induce growth arrest or apoptosis." In 2003 Guzman  added "Cannabinoids - the active components of Cannabis sativa and their derivatives - exert palliative effects in cancer patients by preventing nausea, vomiting and pain and by stimulating appetite. In addition, these compounds have been shown to inhibit the growth of tumour cells in culture and animal models by modulating key cell-signalling pathways. Cannabinoids are usually well tolerated, and do not produce the generalized toxic effects of conventional chemotherapies."
Parolaro et al  concluded "Modulation of the endocannabinoid system interferes with cancer cell proliferation either by inhibiting mitogenic autocrine/paracrine loops or by directly inducing apoptosis; however, the proapoptotic effect of anandamide is not shared by other endocannabinoids and suggests the involvement of non-cannabinoid receptors" Bifulco & Di Marzo  reviewed studies of antitumour activity and concluded "Recently, evidence has accumulated indicating that stimulation of cannabinoid receptors by either THC or the endocannabinoids influence the intracellular events controlling the proliferation and apoptosis of numerous types of cancer cells, thereby leading to anti-tumour effects both in vitro and in vivo. This evidence is reviewed here and suggests that future anti-cancer therapy might be developed from our knowledge of how the endocannabinoid system controls the growth and metastasis of malignant cells."
Hodgkins & Lymphomas: There are few scientific references specifically to research in Hodgkins disease. Abrahamov et al  reported the effects of a study of delta-8-THC in children suffering from haematological cancers and undergoing chemotherapy, noting "Vomiting was completely prevented. The side effects observed were negligible.". However Lockwood  reported a case history of "Marihuana and alcohol intolerance" in a Hodgkin's disease patient.
In a study of lymphobastomas, McKallip et al  found "human tumor cells were also susceptible to apoptosis induced by THC, HU-210, anandamide, and the CB2-selective agonist JWH-015. This effect was mediated at least in part through the CB2 receptors because pretreatment with the CB2 antagonist SR144528 partially reversed the THC-induced apoptosis. Also, because CB2 agonists lack psychotropic effects, they may serve as novel anticancer agents to selectively target and kill tumors of immune origin." Islam et al  noted a "high expression of the cannabinoid receptor 1 (CB1) gene in all Mantle Cell Lymphoma cases analysed"
However Joosten et al  postulated that an overabundance of CB2 receptors in transgenic mice may increase predisposition to leukaemia, and Jorda et al  concluded "a major function of Cb2 receptor expressed on myeloid leukemia cells or normal splenocytes is stimulation of migration"
Summary -side effects of chemotherapy: Levitt  in an early review presentation, suggested:"The use of cannabinoids as cancer chemotherapy anti-emetics represents, in essence, the use of a drug with a relatively undefined mechanism of action to treat the side effects of other drugs, also with relatively undefined mechanisms of action, which are being used to treat cancer, a disease or series of diseases the precise nature of which remains enigmatic." Since LevittÃs review, there have been major advances in cannabinoid pharmacology and in understanding of the cancer disease process. In particular, research by Herkenham et al   demonstrated the presence of numerous cannabinoid receptors in the nucleus of the solitary tract, a brain center that is important in the control of vomiting  .
Although other recently developed anti-emetics are as effective or more effective than oral THC, nabilone or smoked cannabis, for certain individuals unresponsive to conventional anti-emetic drugs, the use of smoked cannabis can provide relief more effectively than oral preparations which may be difficult to swallow or be expelled in vomit before having a chance to take effect. The psychoactive/euphoriant effects of THC or smoked cannabis may provide an improvement in mood, whereas several conventional preparations e.g. phenothiazines such as haloperidol (known as Æmajor tranquillisersÃ and also used in the treatment of psychoses such as schizophrenia), may produce unwanted side effects such as excessive sedation, flattening of mood, and/or distressing physical ÆextrapyramidalÃ symptoms such as uncontrolled or compulsive movements. A 1991 US survey  found public support for marijuana use by cancer patients.
In the USA, synthetic THC (Dronabinol) is available for use as an adjunct to cancer chemotherapy treatment, and in the UK, both the British Medical Association and House of Lords recognised the potential for use of cannabinoids in preventing nausea and vomiting.
Summary - Direct anti-cancer activity of cannabinoids. Some researchers have investigated the link between mental and spiritual state and cancer remission, associating the cannabinoid system with the expression of pleasure on the one hand and stress on the other. Lissoni et al  reviewed the effect of psychospiritual state on cancer growth or suppression, noting "Stress, anxiety and depressive states are associated with immunosuppression and enhanced frequency of tumors. On the other hand, the states of sexual pleasure and spiritual joy enhance the immune efficacy, by counteracting tumor onset and dissemination. The biochemistry of pleasure and immunostimulation is mainly mediated by pineal indoles and cannabinergic substances, whereas that of stress, anxiety and depression is associated with enhanced production of adrenal steroids, opioids and catecholamines."
There would appear to be growing evidence of direct anti-tumour activity of cannabinoids, specifically CB1 and CB2 agonists, in a range of cancer types including brain (gliomas), skin, pituitary, prostate and bowel. The antitumour activity has led in laboratory animals and in-vitro human tissues to regression of tumours, reductions in vascularisation (blood supply) and metastases (secondary tumours), as well as direct inducement of death (apoptosis) among cancer cells. Indeed, the complex interactions of endogenous cannabinoids and receptors is leading to greater scientific understanding of the mechanisms by which cancers develop.
However smoking of cannabis releases a number of non-cannabinoid carcinogens into the lungs and upper respiratory tract, and a number of researchers (notably Tashkin and colleagues) have identified pre-cancerous changes in lung cells. The failure of these researchers to discover significant evidence of actual cancer cells in the lung may be attributed to these anti-cancer activities of cannabinoids including THC counteracting the effects of other carcinogens in smoked cannabis.
 Gralla RJ, Itri LM, Pisko SE, et al. 1981. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy induced nausea vomiting. New England Journal of Medicine 305:905-909.
 Davis CJ. 1995. Emesis research: A concise history of the critical concepts and experiments. In: Reynolds DJ' Andrews PL, Davis CJ, Editors. Serotonin and the scientific basis of anti-emetic therapy. Oxford: Oxford Clinical Communications. Pp.9-24.
 Hesketh PJ, Kris MG, Grunberg SM, Beck T. Hainsworth ID, Harker G. Aapro MS, Gandara D, Lindley CM. 1997. Proposal for classifying the acute emetogenicity of cancer chemotherapy. Journal of Clinical Oncology 15:103-109.
 British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam, The Netherlands: Harwood Academic Publishers.
 DeMulder PH, Seynaeve C, Vermorker JB, et al. 1990. Ondansetron compared with highdose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting: A multicenter, randomized, double-blind, crossover study. Annals of Internal Medicine 113:834-840.
 Jamshidi N, Taylor DA.  Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats.Br J Pharmacol. 134(6):1151-4.
 Inui A.  Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 52(2):72-91.
 Croxford JL.  Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 17(3):179-202.
 Walsh D, Nelson KA, Mahmoud FA.  Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 11(3):137-43. Epub 2002 Aug 21.
 Grotenhermen F.  Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 42(4):327-60
 Parker LA, Mechoulam R, Schlievert C, Abbott L, Fudge ML, Burton P.  Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl). 166(2):156-62. Epub 2003 Jan 15.
 Zurcher G.  [Anorectic syndrome] [Article in German] Z Gastroenterol. 2002 Apr;40 Suppl 1:S71-S5.
 Russmann S, Winkler A, Lovblad KO, Stanga Z, Bassetti C  Lethal ischemic stroke after cisplatin-based chemotherapy for testicular carcinoma and cannabis inhalation. Eur Neurol. 2002;48(3):178-80.
 Drewe J.  [In Process Citation] [Article in German] Ther Umsch. 2003 Jun;60(6):313-6.
 Gardner B, Zhu LX, Sharma S, Tashkin DP, Dubinett SM  Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J. 17(14):2157-9. Epub 2003 Sep 04.
 Sallan SE, Zinberg NE, Frei E. 1975. Antiemetic effect of delta-9-THC in patients receiving cancer chemotherapy. New England Journal of Medicine 293 :795-797.
 Chang AK, Shiling DJ, Stillman RC, et al. 1979. Delta-9-tetrahydrocannabinol as an Antiemetic in patients receiving high-dose methotrexate: A prospective, randomized evaluation. Annals of Internal Medicine 91:819-824.
 Frytak S. Moertel CG, O'Fallon J. et al. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in patients treated with cancer chemotherapy: a double comparison with prochloperazine and a placebo. Annals of Internal Medicine 91 :825-830.
 Orr LE, McKernan JF, Bloome B. 1980. Antiemetic effect of Tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Archives of Internal Medicine 140:1431
 Lucas VS Jr & Laszlo J (1980) D9 THC for refractory vomiting induced by cancer chemotherapy JAMA 243 pp1241-1243
 Chang AK, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, Rosenberg SA. (1981). A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47:1746-51.
 Niedhart J, Gagen M, Wilson H & Young D (1981) Comparative trial of the antiemetic effects of THC and haloperidol. J Clin Pharmacol 21 p385
 Gralla RJ, Itri LM, Pisko SE, et al. (1981). Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy induced nausea vomiting. New England Journal of Medicine 305:905-909.
 Ungerleider JT, Andrysiak TA, Fairbanks L, Goodnight J, Sarna G & Jamieson K. (1982). Cannabis and Cancer Chemotherapy, a comparison of oral D9 THC and prochlorperazine. Cancer 50 pp636-645.
 LaneM, Vogel CL, & Ferguson J (1991) Dronabinol and prochlorperazine in combination are better than either agent alone for treatement of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncologists 8 p236
 Nagy CM, Furnas BE, Einhorn LH, & Bond WH (1978) Nabilone: antiemetic crossover study in cancer chemotherapy patients. Proc Am Soc Cancer Research 19 p30
 Herman TS, Einhorn LH, Jones SE, Nagy CM, Chester AB, Dean JC, Furnas B, Williams ST, Leigh SA, Dorr RT & Moon TE (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. NEJM 300 pp1295-1297
 Einhorn LH, Nagy C, Furnas B & Williams SD (1981) Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol 21 pp645-695
 Wada JK, Bogdon DL, Gunnell JC, Hum GJ, Gota CH & Rieth TE (1982) Double-blind randomised crossover trial of nabilone vs placebo in cancer chemotherapy. Cancer Treatment Reviews 9 (supplement B) pp39-44
 Levitt M (1982) Nabilone vs placebo in treatment of chemotherapy induced nausea and vomiting in cancer patients. Cancer Treatment Reviews 9 (supplement B) pp49-53
 Johannson R, Kikku P & Groenroos M (1982) A double-blind controlled trial of nabilone vs prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treatment Reviews 9 (supplement B) pp25-33
 Ahmedzal S, Carlyle DL, Calder IT & Moran F (1983) Antiemetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 48 pp67-663
 Niiranen A & Mattson K (1985) A crossover comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. Am J Clin Oncology 8 pp36-340
 Jones SE, Durant JR, Greco FA & Roberstone A (1982) A multi-institutional phase III study of nabilone vs placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Review 9 pp455-485
 Niederle N, Schutte J & Schmidt CG (1986) Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klinische Wochenschrift 64 pp 362-265
 Pomeroy M, Fennelly JJ, Towers M (19867) Prospective randomised double-blind trial of nabilone vs domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemotherapy & Pharmacology 17 pp 285-288
 Dalzell AM, Bartlett H Lilleyman JS (1986) Nabilone: an alternative antiemetic for cancer chemotherapy Ach Diseases of Childhood. 89 pp1314-1319
 Chan HSL, Correia JA & MacLeod SM (1987) Nabilone versus prochlorperazine for control of cancer chemotherapy induced emesis in children - a double blind crossover trial. Pediatrics 79 pp946-952.
 Vinciguerra V, Moore T. Brennan E. 1988. Inhalation marijuana as an antiemetic for cancer chemotherapy. New York State Journal of Medicine 88:525-527.
 Levitt M, Faiman C, Hawks R. et al. 1984. Randomized double-blind comparison of delta-9- THC and marijuana as chemotherapy antiemetics. Proceedings of the American Society for Clinical Oncology 3:91.
 Lindgren JE, Ohlsson A, Agurell S. Hollister LE, Gillespie H. 1981. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology (Berl) 74:208-12.
 Ohlsson A, Lindgren J-E, Wahlen A, Agurell S. Hollister L E, Gillespie HK. 1980. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clinical Pharmacology and Therapeutics 28:409-416.
 Huestis MA, Henningfield JE, Cone EJ. 1992. Blood Cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. Journal of Analytical Toxicology 16:276-282.
 Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. 1999. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385-394.
 British Medical Association. 1997. Therapeutic uses of cannabis. Amsterdam, The Netherlands: Harwood Academic Publishers.
 Janet E. Joy, Stanley J. Watson, Jr., and John A. Benson, Jr., Editors (1999) Marijuana and Medicine - Assessing the Science Base. Institute of Medicine/National Academy Press Washington, D.C
 House of Lords (1998) op cit paras 5.12, 8.9-8.11
 Blazquez C, Casanova ML, Planas A, Del Pulgar TG, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M.  Inhibition of tumor angiogenesis by cannabinoids. FASEB J. 17(3):529-31. Epub 2003 Jan 02.
 Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramon y Cajal S, Guzman M.  Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res.61(15):5784-9.
 Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M.  Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest. 111(1):43-50
 Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z, De Petrocellis L.  Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.Biochem J. 358(Pt 1):249-55
 De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V.  Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol. 16(4):297-302.
 Fowler CJ, Jonsson KO, Andersson A, Juntunen J, Jarvinen T, Vandevoorde S, Lambert DM, Jerman JC, Smart D.  Inhibition of C6 glioma cell proliferation by anandamide, 1-arachidonoylglycerol, and by a water soluble phosphate ester of anandamide: variability in response and involvement of arachidonic acid. Biochem Pharmacol. 66(5):757-67.
 Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M  Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis.FASEB J. 17(12):1771-3. Epub 2003 Jul 03.
 Mimeault M, Pommery N, Wattez N, Bailly C, Henichart JP.  Anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production. Prostate. 56(1):1-12.
 Recht LD, Salmonsen R, Rosetti R, Jang T, Pipia G, Kubiatowski T, Karim P, Ross AH, Zurier R, Litofsky NS, Burstein S.  Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid. Biochem Pharmacol. 62(6):755-63.
 Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'argenio G, Scaglione G, Bifulco M, Sorrentini I, Di Marzo V.  Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 125(3):677-87.
 Jacobsson SO, Wallin T, Fowler CJ.  Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther. 2001 Dec;299(3):951-9.
 Gomez del Pulgar T, Velasco G, Sanchez C, Haro A, Guzman M.  De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochem J. 363(Pt 1):183-8.
 Gomez Del Pulgar T, De Ceballos ML, Guzman M, Velasco G.  Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem. 277(39):36527-33. Epub 2002 Jul 19.
 Gonzalez S, Mauriello-Romanazzi G, Berrendero F, Ramos JA, Franzoni MF, Fernandez-Ruiz J.  Decreased cannabinoid CB1 receptor mRNA levels and immunoreactivity in pituitary hyperplasia induced by prolonged exposure to estrogens. Pituitary. 3(4):221-6.
 Pagotto U, Marsicano G, Fezza F, Theodoropoulou M, Grubler Y, Stalla J, Arzberger T, Milone A, Losa M, Di Marzo V, Lutz B, Stalla GK.  Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab. 86(6):2687-96
 Rubovitch V, Gafni M, Sarne Y.  The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res. 101(1-2):93-102.
 Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, De Petrocellis L, Di Marzo V.  Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 15(14):2745-7. Epub 2001 Oct 29.
 Guzman M, Sanchez C, Galve-Roperh I.  Cannabinoids and cell fate. Pharmacol Ther. 95(2):175-84.
 Guzman M.  Cannabinoids: potential anticancer agents. Nat Rev Cancer. 3(10):745-55
 Parolaro D, Massi P, Rubino T, Monti E.  Endocannabinoids in the immune system and cancer. Prostaglandins Leukot Essent Fatty Acids. 66(2-3):319-32.
 Bifulco M, Di Marzo V. [The endocannabinoid system as a target for the development of new drugs for cancer therapy] [Article in Italian] Recenti Prog Med. 94(5):194-8.
 Abrahamov A, Abrahamov A, Mechoulam R.  An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci. 56(23-24):2097-102
 Lockwood AH.  Marihuana and alcohol intolerance in Hodgkin's disease. N Engl J Med. 288(10):526.
 McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M.  Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 100(2):627-34.
 Islam TC, Asplund AC, Lindvall JM, Nygren L, Liden J, Kimby E, Christensson B, Smith CI, Sander B.  High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia. 2003 Sep;17(9):1880-90.
 Joosten M, Valk PJ, Jorda MA, Vankan-Berkhoudt Y, Verbakel S, van den Broek M, Beijen A, Lowenberg B, Delwel R.  Leukemic predisposition of pSca-1/Cb2 transgenic mice. Exp Hematol. 30(2):142-9.
 Jorda MA, Verbakel SE, Valk PJ, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agro A, Lowenberg B, Delwel R.  Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood. 99(8):2786-93.
 Levitt M, Faiman C, Hawks R. et al. 1984. Randomized double-blind comparison of delta-9- THC and marijuana as chemotherapy antiemetics. Proceedings of the American Society for Clinical Oncology 3:91.
 Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience 11 :563-583.
 Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC. (1990). Cannabinoid receptor localization in the brain. Proceedings of the National Academy of Sciences of the United States of America 87:1932- 1936.
 Miller AD. 1998. Nausea and vomiting: Underlying mechanisms and upcoming treatments Journal of the Japan Broncho-Esophagological Society 49:57-64.
 Treaster JB.  Survey finds support for marijuana use by cancer patients.NY Times (Print). 1991 May 1;:D22.
 Lissoni P, Cangemi P, Pirato D, Roselli MG, Rovelli F, Brivio F, Malugani F, Maestroni GJ, Conti A, Laudon M, Malysheva O, Giani L.  A review on cancer--psychospiritual status interactions. Neuroendocrinol Lett. 22(3):175-80.